PLD2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of MCF-7 cells using PLD2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Immunofluorescence analysis of SK-OV-3 cells using PLD2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PLD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human renal tissues using PLD2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using PLD2 mouse mAb with DAB staining.    

  
  

Phospholipase D2 (PLD2) is a member of the phospholipase D family, enzymes that hydrolyze phosphatidylcholine to generate phosphatidic acid (PA), a key lipid second messenger involved in cellular signaling, membrane trafficking, and cytoskeletal reorganization. PLD2 localizes primarily to the plasma membrane and endosomal compartments, where it regulates critical processes like cell proliferation, survival, and migration. Unlike its isoform PLD1. PLD2 exhibits constitutive activity but can be further stimulated by extracellular signals, including growth factors and cytokines, via mechanisms involving small GTPases (e.g., ARF, Rho) and protein kinase C. Dysregulation of PLD2 has been implicated in cancer progression, immune disorders, and neurodegenerative diseases, making it a potential therapeutic target.

PLD2 antibodies are essential tools for studying the enzyme's expression, localization, and function. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess PLD2 levels in tissues or cultured cells. Specific PLD2 antibodies help distinguish it from PLD1. enabling isoform-specific research. Additionally, neutralizing antibodies or inhibitory reagents targeting PLD2 are explored for their potential to suppress oncogenic signaling or inflammatory responses in preclinical models. The development and validation of high-affinity, selective PLD2 antibodies remain critical for advancing both basic research and therapeutic strategies aimed at modulating PLD2-associated pathways.